Drug Approval | July 14, 2023
Lupin receives approval from USFDA for Chlorpromazine Hydrochloride Tablets USP
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
This product will be launched through Granules Consumer Health (GCH) division
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Advances clinical research capabilities with leading regulatory grade registries platform
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD®) had estimated annual sales of USD 1 million in the U.S. (IQVIA MAT March 2023)
Subscribe To Our Newsletter & Stay Updated
